Podcasts

Episode 22 | Accelerating Progress in Oncogene-driven Lung Cancer

Dr Deme Karikios, Dr Wanda Cui and A/Prof Chris Karapetis discuss the advances in oncogene-driven lung cancer and what this means for trial design, patients and treatment practices in Australia.

Accelerating Progress in Oncogene-driven Lung Cancer

Episode Summary

Join us for the latest TOGA podcast about Accelerating Progress in Oncogene-driven Lung Cancer. Dr Deme Karikios, Dr Wanda Cui and A/Prof Chris Karapetis discuss the advances in oncogene-driven lung cancer and what this means for trial design, patients and treatment practices in Australia. We examine the survival data for the common and not so common mutated lung cancers, as well as the future view.

Show Hosts

This episode’s host are:

  • Dr Deme Karikios, Medical Oncologist and Director of Clinical Trials, Nepean Cancer Centre
  • Dr Wanda Cui, Medical Oncologist, Peter MacCallum Cancer Centre
  • A/Prof Chris Karapetis, Head of the Department of Medical Oncology and Director of Clinical Research, Flinders Medical Centre

Play Episode 22 | Accelerating Progress in Oncogene-driven Lung Cancer

More Podcasts

Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.
Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.
Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.
Host A/Prof Rachel Roberts-Thomson leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer.
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Malinda Itchins, a medical oncologist and clinician researcher at Royal North Shore Hospital
In this episode, we welcome A/Prof Surein Arulananda, the interim Director of Medical Oncology and Thoracic Oncology Trials Lead at Monash Health.